Gustavo Larsen
YOU?
Author Swipe
View article: Long-Lasting Cognitive and Physical Impairment After Recreational Use of the Semisynthetic Cannabinoid Hexahydrocannabinonyl (HHC-C9): A Case Report
Long-Lasting Cognitive and Physical Impairment After Recreational Use of the Semisynthetic Cannabinoid Hexahydrocannabinonyl (HHC-C9): A Case Report Open
Background and Clinical Significance: The recreational use of semisynthetic cannabinoids (SSCs) is increasing, and SSCs account for more than 40% of all new substances reported at the European level. Although designed to mimic the effects …
View article: Surface antibody changes protein corona both in human and mouse serum but not final opsonization and elimination of targeted polymeric nanoparticles
Surface antibody changes protein corona both in human and mouse serum but not final opsonization and elimination of targeted polymeric nanoparticles Open
Background Nanoparticles represent one of the most important innovations in the medical field. Among nanocarriers, polymeric nanoparticles (PNPs) attracted much attention due to their biodegradability, biocompatibility, and capacity to inc…
View article: Supplementary Table 1 from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma
Supplementary Table 1 from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma Open
Clinical characteristics of patients included in TMA
View article: Supplementary Table 2 from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma
Supplementary Table 2 from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma Open
Genome-wide expression analysis of sh-control vs. sh-control with TMZ
View article: Supplementary Table 3 from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma
Supplementary Table 3 from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma Open
Genome-wide expression analysis of sh-p105 vs. sh-p105 with TMZ
View article: Supplementary Table 2 from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma
Supplementary Table 2 from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma Open
Genome-wide expression analysis of sh-control vs. sh-control with TMZ
View article: Data from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma
Data from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma Open
Alkylating chemotherapy is a central component of the management of glioblastoma (GBM). Among the factors that regulate the response to alkylation damage, NF-κB acts to both promote and block cytotoxicity. In this study, we used genome-wid…
View article: Supplemental Figures 1-8 from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma
Supplemental Figures 1-8 from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma Open
Figure S1 shows the results of the p50 dependent gene expression analysis, Figure S2 shows MALAT1 expression in different GBM cell lines, Figure S3 demonstrates a schematic of putative binding sites on MALAT1, Figure S4 shows killing and s…
View article: Supplementary Table 3 from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma
Supplementary Table 3 from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma Open
Genome-wide expression analysis of sh-p105 vs. sh-p105 with TMZ
View article: Supplementary Table 4 from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma
Supplementary Table 4 from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma Open
Table of significantly altered genes from sh-control cells with a FDR < 0.01
View article: Supplementary Table 4 from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma
Supplementary Table 4 from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma Open
Table of significantly altered genes from sh-control cells with a FDR < 0.01
View article: Supplementary Table 1 from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma
Supplementary Table 1 from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma Open
Clinical characteristics of patients included in TMA
View article: Data from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma
Data from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma Open
Alkylating chemotherapy is a central component of the management of glioblastoma (GBM). Among the factors that regulate the response to alkylation damage, NF-κB acts to both promote and block cytotoxicity. In this study, we used genome-wid…
View article: Supplemental Figures 1-8 from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma
Supplemental Figures 1-8 from Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma Open
Figure S1 shows the results of the p50 dependent gene expression analysis, Figure S2 shows MALAT1 expression in different GBM cell lines, Figure S3 demonstrates a schematic of putative binding sites on MALAT1, Figure S4 shows killing and s…
View article: Supplementary Data Legends from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide
Supplementary Data Legends from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide Open
Supplementary Data Legends. Legends for supplementary data presented for publication.
View article: Data from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide
Data from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide Open
Temozolomide is used widely to treat malignant glioma, but the overall response to this agent is generally poor. Resistance to DNA-damaging drugs such as temozolomide has been related to the induction of antiapoptotic proteins. Specificall…
View article: Supplementary figure 4 from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide
Supplementary figure 4 from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide Open
Supplementary figure 4. A, clonogenic assay in U87 cells treated with Fas ligand (30 ng/ml) and/or FNAb (1 μg/ml). B, clonogenic assay in U87 cells transfected with the indicated siRNA following treatment with vehicle or Fas ligand (30 ng/…
View article: Supplementary figure 2 from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide
Supplementary figure 2 from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide Open
Supplementary figure 2. A, ChIP using DCR1 promoter specific primers. Quantitative data show chromatin enrichment of Bcl3 relative to input after controlling for non-specific binding using anti-histone H1 (positive control) and anti-IgG, n…
View article: Supplementary figure 5 from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide
Supplementary figure 5 from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide Open
Supplementary figure 5. Kaplan-Meier survival curves from the REMBRANDT database stratified based on DCR1 mRNA expression level.
View article: Supplementary figure 4 from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide
Supplementary figure 4 from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide Open
Supplementary figure 4. A, clonogenic assay in U87 cells treated with Fas ligand (30 ng/ml) and/or FNAb (1 μg/ml). B, clonogenic assay in U87 cells transfected with the indicated siRNA following treatment with vehicle or Fas ligand (30 ng/…
View article: Data from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide
Data from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide Open
Temozolomide is used widely to treat malignant glioma, but the overall response to this agent is generally poor. Resistance to DNA-damaging drugs such as temozolomide has been related to the induction of antiapoptotic proteins. Specificall…
View article: Supplementary figure 1Figure S1 from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide
Supplementary figure 1Figure S1 from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide Open
Supplementary figure 1. A, Venn diagram showing overview of genes significantly (FDR < 0.05) altered in response to TMZ in U87 cells stably expressing control or p105 shRNA. DCR1 (TNFRSF10C) was identified as a gene specific to control cel…
View article: Supplementary figure 2 from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide
Supplementary figure 2 from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide Open
Supplementary figure 2. A, ChIP using DCR1 promoter specific primers. Quantitative data show chromatin enrichment of Bcl3 relative to input after controlling for non-specific binding using anti-histone H1 (positive control) and anti-IgG, n…
View article: Supplementary Data Legends from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide
Supplementary Data Legends from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide Open
Supplementary Data Legends. Legends for supplementary data presented for publication.
View article: Supplementary figure 3 from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide
Supplementary figure 3 from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide Open
Supplementary figure 3. A, annexin V binding in U251 cells treated with vehicle or temozolomide (TMZ, 100 μM) following transfection with the indicated siRNA. B, clonogenic assay in A172 cells transfected with the indicated siRNA following…
View article: Supplementary figure 1Figure S1 from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide
Supplementary figure 1Figure S1 from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide Open
Supplementary figure 1. A, Venn diagram showing overview of genes significantly (FDR < 0.05) altered in response to TMZ in U87 cells stably expressing control or p105 shRNA. DCR1 (TNFRSF10C) was identified as a gene specific to control cel…
View article: Supplementary figure 3 from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide
Supplementary figure 3 from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide Open
Supplementary figure 3. A, annexin V binding in U251 cells treated with vehicle or temozolomide (TMZ, 100 μM) following transfection with the indicated siRNA. B, clonogenic assay in A172 cells transfected with the indicated siRNA following…
View article: Supplementary figure 5 from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide
Supplementary figure 5 from Decoy Receptor DcR1 Is Induced in a p50/Bcl3–Dependent Manner and Attenuates the Efficacy of Temozolomide Open
Supplementary figure 5. Kaplan-Meier survival curves from the REMBRANDT database stratified based on DCR1 mRNA expression level.
View article: Method of manufacturing fibrous hemostatic bandages
Method of manufacturing fibrous hemostatic bandages Open
A method of manufacturing a sturdy and pliable fibrous hemostatic dressing by making fibers that maximally expose surface area per unit weight of active ingredients as a means for aiding in the clot forming process and as a means of minimi…